JP2022523524A5 - - Google Patents

Info

Publication number
JP2022523524A5
JP2022523524A5 JP2021549919A JP2021549919A JP2022523524A5 JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5 JP 2021549919 A JP2021549919 A JP 2021549919A JP 2021549919 A JP2021549919 A JP 2021549919A JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5
Authority
JP
Japan
Application number
JP2021549919A
Other languages
Japanese (ja)
Other versions
JP2022523524A (ja
JPWO2020173897A5 (https=
JP7476219B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/054821 external-priority patent/WO2020173897A1/en
Publication of JP2022523524A publication Critical patent/JP2022523524A/ja
Publication of JP2022523524A5 publication Critical patent/JP2022523524A5/ja
Publication of JPWO2020173897A5 publication Critical patent/JPWO2020173897A5/ja
Application granted granted Critical
Publication of JP7476219B2 publication Critical patent/JP7476219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549919A 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質 Active JP7476219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19000100.8 2019-02-26
EP19000100 2019-02-26
PCT/EP2020/054821 WO2020173897A1 (en) 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3

Publications (4)

Publication Number Publication Date
JP2022523524A JP2022523524A (ja) 2022-04-25
JP2022523524A5 true JP2022523524A5 (https=) 2022-12-13
JPWO2020173897A5 JPWO2020173897A5 (https=) 2022-12-13
JP7476219B2 JP7476219B2 (ja) 2024-04-30

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549919A Active JP7476219B2 (ja) 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質

Country Status (14)

Country Link
US (1) US12486330B2 (https=)
EP (1) EP3931209A1 (https=)
JP (1) JP7476219B2 (https=)
KR (1) KR20210133254A (https=)
CN (1) CN113474359B (https=)
AU (1) AU2020229436B2 (https=)
BR (1) BR112021016829A2 (https=)
CA (1) CA3124441A1 (https=)
IL (1) IL284687B2 (https=)
MA (1) MA55069A (https=)
MX (1) MX2021010039A (https=)
SG (1) SG11202106353VA (https=)
WO (1) WO2020173897A1 (https=)
ZA (1) ZA202104287B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
JP2024513264A (ja) * 2021-04-05 2024-03-22 サイトヴィア セラピューティクス, エルエルシー Nkp46及びgpc3を標的とする二重特異性抗体、並びにその使用方法
CA3216342A1 (en) * 2021-04-23 2022-10-27 Hassan ISSAFRAS Anti-gpc3 antibodies, multispecific antibodies and methods of use
JP2024522078A (ja) * 2021-05-21 2024-06-11 ベイジーン スウィッツァーランド ゲーエムベーハー 抗gpc3及び抗cd137多重特異性抗体ならびにそれらの使用方法
CA3228064A1 (en) * 2021-08-12 2023-02-16 Shanghai Jmt-Bio Technology Co., Ltd. Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN113912699A (zh) * 2021-10-14 2022-01-11 江南大学 一种新型治疗乳腺癌的fgf类似物及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
WO2023174401A1 (zh) * 2022-03-18 2023-09-21 映恩生物制药(苏州)有限公司 Gpc3抗体药物偶联物及其用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
CN119613552B (zh) * 2024-07-23 2025-11-28 艾可泰科(浙江)控股有限公司 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
WO2007107563A2 (en) 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2014066328A1 (en) * 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
RU2019124709A (ru) * 2017-01-06 2021-02-08 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
EP3638700B8 (en) * 2017-06-14 2024-09-04 Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation Proteinaceous heterodimer and use thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022523524A5 (https=)
CL2026000398A1 (es) Conjugados de neodegradadores.
BR112023009656A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)